{
  "name": "RAPA",
  "symbol": "$RAPA",
  "description": "RapaMeta Eternum™\nresearch‑grade combo concept uniting mTOR inhibition and AMPK modulation for systemic longevity biology.\n\nMechanistic concept\nRapaMeta Eternum™ is positioned as a dual‑axis longevity stack that integrates:\nRapamycin, a well‑validated inhibitor of mTORC1 that extends lifespan and delays multiple age‑related pathologies in mice, even when started late in life.\n\nMetformin, a front‑line metabolic therapeutic that reduces hepatic gluconeogenesis, improves peripheral insulin sensitivity, and modestly activates AMPK‑linked pathways.\n\nIn genetically heterogeneous HET3 mice, chronic dietary rapamycin (14 ppm encapsulated) extended lifespan but induced glucose intolerance and mild insulin resistance, particularly in males. Metformin at 0.1% dietary inclusion alone did not meaningfully change glucose tolerance, yet in combination it reshaped the metabolic phenotype in a sex‑specific way. RapaMeta Eternum™ encodes this synergy: longevity signaling via mTORC1 ‑linked geroprotecti",
  "image": "https://aquamarine-past-ladybug-185.mypinata.cloud/ipfs/bafybeihle45ewja5ishs2pjlznvjhnv5o55xovn7eejlqnvtucfpwc3t3e",
  "external_url": "https://www.pump.science/"
}